Helicobacter pylori stimulates inducible nitric oxide synthase in diverse topographical patterns in various gastroduodenal disorders.
Overproduction of nitric oxide by inducible nitric oxide synthase (iNOS) acts cytotoxically and contributes to inflammation. We explored the roles of iNOS in the pathogenesis of Helicobacter pylori-associated diseases. Using reverse-transcribed PCR, we examined topographical patterns of iNOS mRNA expression in the gastroduodenal mucosa in H. pylori-negative controls and H. pylori-positive patients with duodenal ulcer (DU), gastric ulcer (GU), and ulcer-free gastritis. iNOS expression showed topographical variations among the tested disorders. As compared to controls, DU had a significantly higher expression of iNOS mRNA in the duodenum, GU in the antrum and duodenum, and gastritis in the antrum and corpus. H. pylori eradication yielded a significant reduction of iNOS mRNA in the duodenum of DU and in the antrum of GU. Diverse topographical patterns of H. pylori-induced iNOS expression may contribute to mechanisms by which H. pylori elicits different clinical disorders.
Kaise
Mitsuru
M
Department of Gastroenterology, Toshiba General Hospital, Tokyo, Japan.
Miwa
Jun
J
Iihara
Kuniko
K
Suzuki
Nobuaki
N
Oda
Yoshio
Y
Ohta
Yasuhiko
Y
D000658:Amoxicillin / Q000008:administration & dosage; D000897:Anti-Ulcer Agents / Q000008:administration & dosage; D001706:Biopsy; D017291:Clarithromycin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000201:enzymology / Q000382:microbiology*; D016145:Endoscopy, Digestive System; D004790:Enzyme Induction / Q000187:drug effects / Q000502:physiology; D005753:Gastric Mucosa / Q000201:enzymology / Q000382:microbiology / Q000473:pathology; D005756:Gastritis / Q000188:drug therapy / Q000201:enzymology / Q000382:microbiology*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects / Q000502:physiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007124:Immunoenzyme Techniques; D007413:Intestinal Mucosa / Q000201:enzymology / Q000382:microbiology / Q000473:pathology; D019001:Nitric Oxide Synthase / Q000096:biosynthesis* / Q000235:genetics; D052247:Nitric Oxide Synthase Type II; D009853:Omeprazole / Q000008:administration & dosage; D011706:Pyloric Antrum / Q000201:enzymology / Q000382:microbiology / Q000473:pathology; D012333:RNA, Messenger / Q000235:genetics
D000897:Anti-Ulcer Agents; D012333:RNA, Messenger; D000658:Amoxicillin; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D017291:Clarithromycin; D009853:Omeprazole